6173 results
Cells,
Volume 13, Issue 19, 30 5 2024, Pages 1636
Pulmonary and Systemic Immune Profiles Following Lung Volume Reduction Surgery and Allogeneic Mesenchymal Stromal Cell Treatment in Emphysema.
Jia L, Li N, van Unen V, Zwaginga JJ, Braun J, Hiemstra PS, Koning F, Khedoe PPSJ, Stolk J
Emphysema in patients with chronic obstructive pulmonary disease (COPD) is characterized by progressive inflammation. Preclinical studies suggest that lung volume reduction surgery (LVRS) and mesenchymal stromal cell (MSC) treatment dampen inflammation. We investigated the effects of bone marrow-derived MSC (BM-MSC) and LVRS on circulating and pulmonary immune cell profiles in emphysema patients using mass cytometry. Blood and resected lung tissue were collected at the first LVRS (L1). Following...
Abstract
Cited 1 times since 2024 (1.8 per year)
source: EuropePMC
JACC. Clinical electrophysiology,
Volume 10, Issue 12, 25 4 2024, Pages 2613-2624
Ventricular Tachycardia Substrates in Children and Young Adults With Repaired Tetralogy of Fallot.
Wallet J, Kimura Y, Blom NA, Jongbloed MRM, Bertels RA, Hazekamp MG, Zeppenfeld K
Background: Patients with repaired tetralogy of Fallot (rTOF) have a time-dependent increased risk of ventricular tachycardia (VT). Slow conducting anatomical isthmuses (SCAIs) are the dominant VT substrates in adults with rTOF. It is unknown if they are present at younger age. Objectives: This study aimed to characterize VT substrates in patients with rTOF
Abstract
Cited 1 times since 2024 (1.8 per year)
source: EuropePMC
European journal of heart failure,
24 4 2024
Sexual dimorphism in the relationships between intramyocardial fat, myocardial fibrosis, and exercise intolerance in heart failure with preserved ejection fraction.
Ng ACT, Dong X, Koepp KE, Obokata M, Sorimachi H, Galloway G, Araoz P, Delgado V, Bax JJ, Borlaug BA
Abstract
Biosensors & bioelectronics,
Volume 267, 24 4 2024, Pages 116791
Dual action electrochemical bandage operated by a programmable multimodal wearable potentiostat.
Bozyel I, Fleming D, Won-Jun K, Rosen PF, Gelston S, Ozdemir D, Kies P, Koscianski C, Karau M, Ay SU, Patel R, Beyenal H
We have developed electrochemical bandage (e-bandage) prototypes that generate the reactive oxygen species hypochlorous acid (HOCl) or hydrogen peroxide (H2O2) for potential use to treat biofilm-infected wounds in humans. We have shown that both e-bandage-generated HOCl and H2O2 kill biofilms in vitro and in infected wounds on mice, with the former being more active in vitro. The H2O2-generating e-bandage, more so than the HOCl-generating e-bandage, was associated with improved healing of infect...
Abstract
Cited 1 times since 2024 (1.7 per year)
source: EuropePMC
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,
Volume 104, Issue 5, 23 4 2024, Pages 881-890
Procedural and clinical impact of intracoronary lithotripsy in heavily calcified aorto-ostial coronary lesions.
Oliveri F, Meijer M, Van Oort MJH, Al Amri I, Bingen BO, Claessen BE, Dimitriu-Leen AC, Kefer J, Girgis H, Vossenberg T, Van der Kley F, Jukema JW, Montero-Cabezas JM
Background: Percutaneous coronary intervention of calcified aorto-ostial lesions (AOL) pose unique challenges due to anatomical propensity for recoil, leading to poorer outcomes compared to non-AOL. Although intravascular lithotripsy (IVL) has shown excellent success and safety in heavily calcified plaques, evidence specific to AOL is limited. This study aims to evaluate the efficacy and safety of IVL in AOL versus non-AOL. Methods: Patients treated with IVL between 2019 and 2023 from an ongoing...
Abstract
Cited 10 times since 2024 (17.5 per year)
source: EuropePMC
Circulation,
Volume 150, Issue 24, 23 4 2024, Pages 1931-1943
Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
Stone GW, Lindenfeld J, Rodés-Cabau J, Anker SD, Zile MR, Kar S, Holcomb R, Pfeiffer MP, Bayes-Genis A, Bax JJ, Bank AJ, Costanzo MR, Verheye S, Roguin A, Filippatos G, Núñez J, Lee EC, Laufer-Perl M, Moravsky G, Litwin SE, Prihadi E, Gada H, Chung ES, Price MJ, Thohan V, Schewel D, Kumar S, Kische S, Shah KS, Donovan DJ, Zhang Y, Eigler NL, Abraham WT, RELIEVE-HF Investigators
Background: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. Methods: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus a placebo procedure, stratified by reduced (≤40%) versus preserved (>40%) LVEF. The primary safety outcome was a composite of device-related or procedure-related major adverse cardiova...
Abstract
European heart journal open,
Volume 4, Issue 5, 23 4 2024, Pages oeae080
Short-term impact of cardiovascular screening by traditional risk assessment or coronary artery calcium score on health-related quality of life: the ROBINSCA trial.
Moldovanu D, de Koning HJ, Vonder M, Gratama JWC, Adriaansen HJ, Roeters van Lennep JE, Vliegenthart R, van der Harst P, Braam RL, van Dijkman PRM, Oudkerk M, van der Aalst CM
Aims: Evidence on the impact of screening for cardiovascular diseases (CVDs) on health-related quality of life (HRQoL) is important for policy decisions about screening implementation and to uncover teachable moments to motivate healthy lifestyle choices. It is unknown whether screening by cardiac computed tomography (CT) scan has a stronger impact on HRQoL than screening by traditional risk prediction models. The study aims to investigate differences in HRQoL across the screening process betwee...
Abstract
Cited 1 times since 2024 (1.7 per year)
source: EuropePMC
Heart & lung : the journal of critical care,
Volume 69, 17 3 2024, Pages 31-39
Modifiable risk factors and motivation for lifestyle change of CVD patients starting cardiac rehabilitation: The BENEFIT study.
Breeman LD, Pérez-Alonso A, Kühling-Romero D, Kraaijenhagen RA, Al-Dhahir I, IJzerman RVH, van Eersel R, Wolstencroft K, Bonten TN, Atsma DE, Chavannes NH, van Gemert-Pijnen L, Kemps HMC, Scholte Op Reimer W, Evers AWM, Janssen VR, BENEFIT consortium
Background: To improve lifestyle guidance within cardiac rehabilitation (CR), a comprehensive understanding of the motivation and lifestyle-supporting needs of patients with cardiovascular disease (CVD) is required. Objectives: This study's purpose is to evaluate patients' lifestyle and their motivation, self-efficacy and social support for change when starting CR. Methods: 1782 CVD patients (69 % male, mean age 62 years) from 7 Dutch outpatient CR centers participated between 2020 and...
Abstract
Research and practice in thrombosis and haemostasis,
Volume 8, Issue 7, 16 3 2024, Pages 102573
The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalization.
Visser C, Berentschot JC, de Jong CMM, Antoni ML, Bek LM, van den Berg-Emons RJG, van den Borst B, Ten Cate H, Ten Cate-Hoek AJ, Braeken DCW, Geelhoed JJM, Heijenbrok-Kal MH, van Kuijk SMJ, Kroft LJM, Leentjens J, Roukens AHE, Cannegieter SC, Klok FA, Kruip MJHA, Hellemons ME, Dutch COVID & Thrombosis Coalition@CovidDutch
Background: COVID-19 patients frequently experience pulmonary embolism (PE), but its long-term consequences remain uncertain. Objectives: To assess the impact of PE in COVID-19 patients on health outcomes at 3 months after hospitalization. Methods: In this multicenter cross-sectional study, we aggregated data from existing databases to evaluate the impact of PE on health outcomes at 3 months after hospitalization. We assessed 1) questionnaires on health-related quality of life (5-level EuroQol 5...
Abstract
Cited 3 times since 2024 (5.1 per year)
source: EuropePMC
Nature medicine,
Volume 30, Issue 11, 16 3 2024, Pages 3223-3235
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could be an option and what the benefit of combination ICI could be. The adaptive BELLINI trial explored whether short combination ICI induces immune activation (primary end point, twofold increase in CD8+ T cells or IFNG), providing a rationale for neoadjuvant ICI without chemotherapy. Here, in...
Abstract
Cited 3 times since 2024 (5 per year)
source: EuropePMC
Communications biology,
Volume 7, Issue 1, 13 2 2024, Pages 1135
Nucleolus and centromere Tyramide Signal Amplification-Seq reveals variable localization of heterochromatin in different cell types.
Kumar P, Gholamalamdari O, Zhang Y, Zhang L, Vertii A, van Schaik T, Peric-Hupkes D, Sasaki T, Gilbert DM, van Steensel B, Ma J, Kaufman PD, Belmont AS
Genome differential positioning within interphase nuclei remains poorly explored. We extended and validated Tyramide Signal Amplification (TSA)-seq to map genomic regions near nucleoli and pericentric heterochromatin in four human cell lines. Our study confirmed that smaller chromosomes localize closer to nucleoli but further deconvolved this by revealing a preference for chromosome arms below 36-46 Mbp in length. We identified two lamina associated domain subsets through their differential nucl...
Abstract
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
Volume 68, Issue 6, 11 2 2024, Pages 815-816
Editor's Choice - Radiation Protection and Pregnancy in Vascular Surgery and Interventional Radiology in the Netherlands.
Jongen JMJ, Samim M, Hoornstra KJPC, Eefting D, van Herwaarden JA, Blok JJ
Abstract
Cited 1 times since 2024 (1.6 per year)
source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation,
Volume 32, Issue 10, 10 2 2024, Pages 338-345
2023 European Society of Cardiology guidelines for the management of acute coronary syndromes : Statement of endorsement by the NVVC.
Zwart B, Claessen BEPM, Damman P, Woudstra P, Vink MA, Balder JW, Dickinson MG, Badings EA, Appelman Y, van 't Hof AWJ, Ten Berg JM, Arslan F
This review discusses the new recommendations in the 2023 European Society of Cardiology guidelines on the management of acute coronary syndrome and provides a perspective on topics specific to clinical practice in the Netherlands, including pre-treatment, antiplatelet agent strategies, the use of risk scores and logistical considerations with regard to the timing of coronary angiography.
Abstract
Atherosclerosis,
Volume 398, 7 1 2024, Pages 118595
Arterial inflammation on [<sup>18</sup>F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I.
Polomski EAS, Kapiteijn EW, Heemelaar JC, van der Kolk AV, Kalisvaart TM, van de Burgt A, Dibbets-Schneider P, van Velden FHP, Seijkens TTP, Stöger JL, Jukema JW, de Geus-Oei LF, Antoni ML
Background and aims: Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment. However, ICIs may increase the immune response to non-tumor cells, possibly resulting in increased arterial inflammation, raising the risk of atherosclerotic events. Nevertheless, malignancies may induce a pro-inflammatory state and the association between ICIs and arterial inflammation remains to be clarified. This study aims to assess differences in increase in arterial inflammation between patients with...
Abstract
Heart rhythm,
6 1 2024, Pages S1547-5271(24)03288-0
Lesion delivery and scar formation in catheter ablation for atrial fibrillation: The DECAAF II trial.
Akoum N, Mekhael M, Bisbal F, Wazni O, McGann C, Lee H, Bardsley T, Greene T, Dean JM, Dagher L, Kholmovski E, Mansour M, Marchlinski F, Wilber D, Hindricks G, Mahnkopf C, Wells D, Jaïs P, Sanders P, Brachmann J, Bax JJ, Morrison-de Boer L, Deneke T, Calkins H, Sohns C, Marrouche N, DECAAF II investigators
Background: The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF. Objective: We evaluated the effect of lesion delivery on ablation-induced scarring and AF recurrence. Methods: Lesions delivered, targetin...
Abstract
Cited 1 times since 2024 (1.6 per year)
source: EuropePMC
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists,
5 1 2024, Pages 15266028241274568
Maximal Systolic Acceleration and Near-Infrared Fluorescence Imaging With Indocyanine Green as Predictors for Successful Lower Extremity Revascularization.
Kruiswijk MW, Willems SA, Koning S, Tange FP, J W M Brouwers J, Peul RC, van Schaik J, Schepers A, Hamming J, van der Bogt KEA, van Rijswijk CSP, Vahrmeijer AL, van den Hoven P, van der Vorst JR
Background: Patients with lower extremity arterial disease (LEAD) frequently require revascularization procedures. Currently used diagnostic methods are insufficient in predicting successful outcomes and focus on macrovascular rather than microvascular state. Several promising modalities to increase diagnostic accuracy are emerging, including maximal systolic acceleration (ACCmax), measured by duplex ultrasound (DUS). For the assessment of tissue perfusion, near-infrared fluorescence (NIR) imagi...
Abstract
The Pediatric infectious disease journal,
Volume 44, Issue 1, 4 1 2024, Pages 83-89
Pediatric Varicella-related Hospitalization in Turkey Between 2008 and 2018: Impact of Universal Single Dose Varicella Vaccine (VARICOMP Study).
Dinleyici EC, Kurugol Z, Devrim I, Bayram N, Dalgic N, Yasa O, Tezer H, Ozdemir H, Ciftci E, Tapisiz A, Celebi S, Hacimustafaoglu M, Yilmaz D, Hatipoglu N, Kara A, VARICOMP Study Group
Background: A single-dose varicella vaccine at 12 months of age was introduced to the National Immunization Program in February 2013 in Turkey. This study aimed to evaluate varicella-related hospitalization in children and the impact of a single-dose live attenuated varicella vaccine over the first 5.5 years of introducing a universal varicella vaccination. Methods: We analyzed data collected from the medical records of children
Abstract
Cited 1 times since 2024 (1.6 per year)
source: EuropePMC
American heart journal,
Volume 278, 2 1 2024, Pages 61-71
Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trial.
De Cock E, Kautbally S, Timmermans F, Bogaerts K, Hanet C, Desmet W, Gurné O, Vranckx P, Hiltrop N, Dujardin K, Vanduynhoven P, Vermeersch P, Pirlet C, Hermans K, Van Reet B, Ferdinande B, Aminian A, Dewilde W, Guédès A, Simon F, De Roeck F, De Vroey F, Jukema JW, Sinnaeve P, Buysschaert I
Introduction: Patients with coronary artery disease (CAD) remain vulnerable to future major atherosclerotic events after revascularization, despite effective secondary prevention strategies. Inflammation plays a central role in the pathogenesis of CAD and recurrent events. To date, there is no specific anti-inflammatory medicine available with proven effective, cost-efficient, and favorable benefit-risk profile, except for colchicine. Initial studies with colchicine have sparked major interest i...
Abstract
Cited 2 times since 2024 (3.2 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 84, Issue 13, 1 1 2024, Pages 1178-1189
Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry.
Schweiger V, Cammann VL, Crisci G, Gilhofer T, Schlenker R, Niederseer D, Chen S, Ebrahimi R, Wenzl F, Würdinger M, Citro R, Vecchione C, Gili S, Neuhaus M, Franke J, Meder B, Jaguszewski M, Noutsias M, Knorr M, Jansen T, D'Ascenzo F, Dichtl W, von Lewinski D, Burgdorf C, Kherad B, Tschöpe C, Sarcon A, Shinbane J, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Roffi M, Banning A, Wolfrum M, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Napp LC, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, Gilyarova E, Shilova A, Gilyarov M, El-Battrawy I, Akin I, Poledniková K, Toušek P, Winchester DE, Massoomi M, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Paolini C, Bilato C, Kobayashi Y, Kato K, Ishibashi I, Himi T, Din J, Al-Shammari A, Prasad A, Rihal CS, Liu K, Schulze PC, Bianco M, Jörg L, Rickli H, Pestana G, Nguyen TH, Böhm M, Maier LS, Pinto FJ, Widimský P, Felix SB, Braun-Dul
Background: The perception of takotsubo syndrome (TTS) has evolved significantly over the years, primarily driven by increased recognition of acute complications and mortality. Objectives: This study aimed to explore temporal trends in demographic patterns, risk factors, clinical presentations, and outcomes in patients with TTS. Methods: Patients diagnosed with TTS between 2004 and 2021 were enrolled from the InterTAK (International Takotsubo) registry. To assess temporal trends, patients were d...
Abstract
Cited 3 times since 2024 (4.7 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 84, Issue 11, 1 1 2024, Pages 994-1006
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.
Zahger D, Schwartz GG, Du W, Szarek M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Jukema JW, Kiss RG, Harrington RA, Moriarty PM, Scemama M, Manvelian G, Pordy R, White HD, Zeiher AM, Fazio S, Geba GP, Steg PG, ODYSSEY OUTCOMES Investigators
Background: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations. Objectives: This study sought to examine relations between triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using prespecified and post hoc analyses of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab)...
Abstract
